Abstract
When spontaneous or postoperative bleeding is due to an established and recognized defect of the hemostatic system, congenital or acquired,the first treatment of choice should be the specific correction of the defect with blood or blood products. A typical example is replacement of the coagulation factor missing or defective in hemophilias. Frequently,however, either no apparent surgical or hematological cause for abnormal bleeding can be recognized, or recognized defects cannot be corrected. In these situations pharmacological compounds that facilitate control of bleeding by potentiating hemostasis would be a welcome therapeutic weapon. Even though a large number of drugs are marketed as “hemostatic agents” that can stop spontaneous and surgical bleeding and prevent or reduce blood losses, very few of them have been proven by adequate clinical trials to be of clinical value.
This work was supported in part by NIH grant R01/HL41136.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988;40:205–14.
Morfini M, Rafanelli D, Filimberti E, et al. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thromb Res 1989;56:169–78.
Brettler DB, Levine PH. Factor concentrates for treatment of hemophilia: Which one to choose? Blood 1989;73:2067–71.
Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates.Lancet 1988;ii:782–5.
Pierce GF, Lusher JM, Brownstein AP, Goldsmith SC, Kessler CM. The use of purified clotting factor concentrates in hemophilia. JAMA 1989;261: 3434–7.
Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan SL. Factor VIII:C concentrate purified from plasma using monoclonal antibodies:Human studies. Blood 1989;73:1859–63.
Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30:81–93.
Mannucci PM, Pareti FI, Holmberg L, Ruggeri ZM, Nilsson IM. Studies on the prolonged bleeding time in von Willebrand disease. J Lab Clin Med 1976;88:662–9.
Kobrinsky NL, Letts RP, Patel RL, et al. DDAVP shortens the bleeding time and decreases blood loss in hemostatically normal subjects undergoing spinal fusion surgery. Ann Intern Med 1987;107:446–50.
Salzman EW, Weinstein MJ, Weitraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986;314:1402–6.
Rocha E, Llorens R, Paramo JA, et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988;77:1319–23.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mannucci, P.M., Federici, A.B. (1991). Principles in the Treatment of Bleeding. In: Sibinga, C.T.S., Das, P.C., Mannucci, P.M. (eds) Coagulation and Blood Transfusion. Developments in Hematology and Immunology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3900-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3900-1_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6740-6
Online ISBN: 978-1-4615-3900-1
eBook Packages: Springer Book Archive